--- Query Results ---

Program:Genetics and Genomics
Test Name:JAK2 V617F Mutational Analysis
Performing Site: University of Alberta Hospital
Performing Dept:Molecular Pathology
Availability:Test set-up on Monday (excluding statutory holidays).
TAT:2 weeks
Preferred Tube/Container:See Specimen Requirements
Specimen Requirements:For Blood Samples:Unopened dedicated tubes are required for Molecular Pathology testing.
1. Any peripheral blood requests will require a CBC and differential to be ordered and processed as per local handling practices.
2. Collect 2 x 4 mL EDTA (lavender) tubes. One tube for CBC/differential and one tube for Molecular Pathology

For Bone Marrow Samples:Unopened dedicated tubes are required for Molecular Pathology testing.
1. Collect a minimum of 2 mL in 1 x 4 mL EDTA (lavender) tube.
Specimen Processing:Do not spin.
Do not freeze.
Keep samples refrigerated until ready for transport.
Specimen Handling:Samples must be received in the Molecular Pathology within 3 days of collection.
Requisition/Form:All requests MUST be submitted on a Molecular Pathology Requisition.
Please provide any pertinent clinical history on the requisition.
Indications:For the investigation of myeloproliferative neoplasms, namely polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Method:Real-time PCR
Method Details:After DNA extraction, the qualitative JAK2 V617F assay is performed using the JAK2 MutaScreenTM Kit (Ipsogen Inc., New Haven, CT). The JAK2 gene sequence spanning the mutation site was amplified using real time polymerase chain reaction with two allele-specific probes that allow detection of the presence of the JAK2 V617F mutation.

The sensitivity of the assay is 2% (2% JAK2 V617F DNA in a normal background).

The mutation may be undetectable in samples containing low numbers of granulocytes or monocytes, or in the presence of a high lymphocyte population, as lymphoid cells generally do not harbor the acquired JAK2 V617F mutation.
Last Updated On:Wednesday, June 21, 2017
Date of Last Review:Jan 2 2018 12:00AM